Subscribe To

Price Alert Latest News Economic Calendar News

MNMD / Numinus Wellness designated as a top research site for MindMed study

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b study on MM-120 (lysergide D-tartrate) for General Anxiety Disorder. The company's Cedar Clinical Research (CCR), located in Draper, Utah, has emerged as the leading site for the study, having successfully enrolled and dosed 19 clinical trial participants thus far. Read More

Demo Live Account See Partner Details

Content Topics

Numinus

Wellness

Designated

Research

Site

Mindmed

Study

Stock

MNMD

Posted: Jun 5 2023, 08:08

Author Name: Proactive Investors

MNMD News

By Seeking Alpha
October 13, 2023

Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized An

By Proactive Investors
June 27, 2023

Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming results

As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups t

By Proactive Investors
June 5, 2023

Numinus Wellness designated as a top research site for MindMed study

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b s

By Business Wire
June 1, 2023

MindMed to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that members of the Company's management team will participate in several June investor c

By Business Wire
May 24, 2023

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's proprietary form of R-MDMA, in a model for autism

By Zacks Investment Research
May 18, 2023

MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study

MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expe

By Proactive Investors
May 9, 2023

MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker says

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical

By Market Watch
April 14, 2023

MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorder

The stock of psychedelics company Mind Medicine Inc. MNMD, +4.82% rose 4% Friday, after the company's Swiss research partners reported positive result

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.